according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

ROTH

Ampicillin sodium salt CELLPURE® ≥ 91%

article number: **HP62**Version: **4.0 en**date of compilation: 2015-08-24
Revision: 2024-03-02

Replaces version of: 2022-06-07

Version: (3)

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Identification of the substance Ampicillin sodium salt CELLPURE® ≥ 91%

Article number HP62

Registration number (REACH)

It is not required to list the identified uses be-

cause the substance is not subject to registration

according to REACH (< 1 t/a).

EC number 200-708-1 CAS number 69-52-3

1.2 Relevant identified uses of the substance or mixture and uses advised against

Relevant identified uses: Laboratory chemical

Laboratory and analytical use

Uses advised against: Do not use for products which come into contact

with foodstuffs. Do not use for private purposes (household). Food, drink and animal feeding-

stuffs.

1.3 Details of the supplier of the safety data sheet

Carl Roth GmbH + Co. KG Schoemperlenstr. 3-5 D-76185 Karlsruhe Germany

Telephone:+49 (0) 721 - 56 06 0 **Telefax:** +49 (0) 721 - 56 06 149 **e-mail:** sicherheit@carlroth.de **Website:** www.carlroth.de

Competent person responsible for the safety data Department Health, Safety and Environment

sheet:

e-mail (competent person): sicherheit@carlroth.de

1.4 Emergency telephone number

Name	Street	Postal code/city	Telephone	Website
National Poisons Information Centre Beaumont Hospital	Beaumont Road	Dublin 9	+353 1 809 2166	https:// www.poisons.ie/

Ireland (en) Page 1 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008 (CLP)

Section	Hazard class	Cat- egory	Hazard class and category	Hazard statement
3.4R	Respiratory sensitisation	1	Resp. Sens. 1	H334
3.45	Skin sensitisation	1	Skin Sens. 1	H317

For full text of abbreviations: see SECTION 16

2.2 Label elements

Labelling according to Regulation (EC) No 1272/2008 (CLP)

Signal word Danger

Pictograms

GHS08



Hazard statements

H317 May cause an allergic skin reaction

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled

Precautionary statements

Precautionary statements - prevention

P261 Avoid breathing dust

P280 Wear protective gloves/eye protection

Precautionary statements - response

P302+P352 IF ON SKIN: Wash with plenty of water

P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor

Labelling of packages where the contents do not exceed 125 ml

Signal word: Danger

Symbol(s)



H317 May cause an allergic skin reaction.

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

P261 Avoid breathing dust.

P280 Wear protective gloves/eye protection. P302+P352 IF ON SKIN: Wash with plenty of water.

P342+P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor.

Ireland (en) Page 2 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

2.3 Other hazards

Results of PBT and vPvB assessment

According to the results of its assessment, this substance is not a PBT or a vPvB.

Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of \geq 0,1%.

SECTION 3: Composition/information on ingredients

3.1 Substances

Name of substance Ampicillin sodium salt

Molecular formula $C_{16}H_{18}N_3NaO_4S$

Molar mass 371,4 g/_{mol}

CAS No 69-52-3

EC No 200-708-1

SECTION 4: First aid measures

4.1 Description of first aid measures



General notes

Take off contaminated clothing.

Following inhalation

Provide fresh air. In case of allergic symptoms, especially in the breathing area, seek medical advice immediately.

Following skin contact

Gently wash with plenty of soap and water. In case of skin reactions, consult a physician.

Following eye contact

Rinse cautiously with water for several minutes. In all cases of doubt, or when symptoms persist, seek medical advice.

Following ingestion

Rinse mouth. Call a doctor if you feel unwell.

4.2 Most important symptoms and effects, both acute and delayed

Allergic reactions (such as skin rashes, hives, asthma or anaphylactic shock), Gastrointestinal complaints, Nausea, Vomiting, Diarrhoea, Dyspnoea

4.3 Indication of any immediate medical attention and special treatment needed

none

Ireland (en) Page 3 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 5: Firefighting measures

5.1 Extinguishing media



Suitable extinguishing media

co-ordinate firefighting measures to the fire surroundings! water, foam, alcohol resistant foam, dry extinguishing powder, ABC-powder

Unsuitable extinguishing media

water jet

5.2 Special hazards arising from the substance or mixture

Combustible.

Hazardous combustion products

In case of fire may be liberated: Nitrogen oxides (NOx), Carbon monoxide (CO), Carbon dioxide (CO₂), Sulphur oxides (SOx)

5.3 Advice for firefighters

In case of fire and/or explosion do not breathe fumes. Fight fire with normal precautions from a reasonable distance. Wear self-contained breathing apparatus.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures



For non-emergency personnel

Avoid contact with skin, eyes and clothes. Do not breathe dust.

6.2 Environmental precautions

Keep away from drains, surface and ground water. Retain contaminated washing water and dispose of it.

6.3 Methods and material for containment and cleaning up

Advice on how to contain a spill

Covering of drains. Take up mechanically.

Advice on how to clean up a spill

Take up mechanically. Control of dust.

Other information relating to spills and releases

Place in appropriate containers for disposal. Ventilate affected area.

6.4 Reference to other sections

Hazardous combustion products: see section 5. Personal protective equipment: see section 8. Incompatible materials: see section 10. Disposal considerations: see section 13.

Ireland (en) Page 4 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 7: Handling and storage

Precautions for safe handling

Provision of sufficient ventilation. Avoid dust formation.

Measures to prevent fire as well as aerosol and dust generation

Removal of dust deposits.

Advice on general occupational hygiene

Wash hands before breaks and after work. Keep away from food, drink and animal feedingstuffs.

7.2 Conditions for safe storage, including any incompatibilities

Store in a dry place. Keep in a cool place.

Incompatible substances or mixtures

Observe hints for combined storage.

Consideration of other advice:

Ventilation requirements

Use local and general ventilation.

Specific designs for storage rooms or vessels

Recommended storage temperature: 2 – 8 °C

7.3 Specific end use(s)

No information available.

SECTION 8: Exposure controls/personal protection

8.1 **Control parameters**

National limit values

Occupational exposure limit values (Workplace Exposure Limits)

Coun try	Name of agent	CAS No	Identifi- er	TWA [mg/ m³]	STEL [mg/ m³]	Ceil- ing-C [mg/ m³]	Nota- tion	Source
IE	dusts, non-specific		OELV	10			i	S.I. No. 619 of 2001
IE	dusts, non-specific		OELV	4			r	S.I. No. 619 of 2001

Notation

Ceiling-C Ceiling value is a limit value above which exposure should not occur

Inhalable fraction Respirable fraction

STEL Short-term exposure limit: a limit value above which exposure should not occur and which is related to a 15-minute period (unless otherwise specified)

Time-weighted average (long-term exposure limit): measured or calculated in relation to a reference period of 8 hours time-weighted average (unless otherwise specified) **TWA**

8.2 **Exposure controls**

Ireland (en) Page 5 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

Individual protection measures (personal protective equipment)

Eye/face protection



Use safety goggle with side protection.

Skin protection



hand protection

Wear suitable gloves. Chemical protection gloves are suitable, which are tested according to EN 374. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. The times are approximate values from measurements at 22 °C and permanent contact. Increased temperatures due to heated substances, body heat etc. and a reduction of the effective layer thickness by stretching can lead to a considerable reduction of the breakthrough time. If in doubt, contact manufacturer. At an approx. 1.5 times larger / smaller layer thickness, the respective breakthrough time is doubled / halved. The data apply only to the pure substance. When transferred to substance mixtures, they may only be considered as a guide.

type of material

NBR (Nitrile rubber)

material thickness

>0,11 mm

breakthrough times of the glove material

>480 minutes (permeation: level 6)

other protection measures

Take recovery periods for skin regeneration. Preventive skin protection (barrier creams/ointments) is recommended.

Respiratory protection





Respiratory protection necessary at: Dust formation. Particulate filter device (EN 143). P2 (filters at least 94 % of airborne particles, colour code: White).

Environmental exposure controls

Keep away from drains, surface and ground water.

Ireland (en) Page 6 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 9: Physical and chemical properties

Information on basic physical and chemical properties 9.1

Physical state solid

Form powder

Colour whitish - yellow Odour characteristic

215 °C (slow decomposition) Melting point/freezing point

Boiling point or initial boiling point and boiling not determined

range

Flammability this material is combustible, but will not ignite

readily

Lower and upper explosion limit not determined not applicable Flash point Auto-ignition temperature not determined

>215 °C Decomposition temperature

pH (value) 8 – 10 (in aqueous solution: $100 \, \text{g/}_{l}$, $20 \, \text{°C}$)

not relevant Kinematic viscosity

Solubility(ies)

50 ^g/_l at 20 °C Water solubility

Partition coefficient

Partition coefficient n-octanol/water (log value): this information is not available

not determined Vapour pressure

Density and/or relative density

not determined Density

Relative vapour density Information on this property is not available.

No data available. Particle characteristics

Other safety parameters

Oxidising properties none

9.2 Other information

> Information with regard to physical hazard hazard classes acc. to GHS classes:

(physical hazards): not relevant

There is no additional information. Other safety characteristics:

Ireland (en) Page 7 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 10: Stability and reactivity

10.1 Reactivity

The product in the delivered form is not dust explosion capable; the enrichment of fine dust however leads to the danger of dust explosion.

10.2 Chemical stability

The material is stable under normal ambient and anticipated storage and handling conditions of temperature and pressure.

10.3 Possibility of hazardous reactions

Violent reaction with: strong oxidiser

10.4 Conditions to avoid

Keep away from heat. Decompostion takes place from temperatures above: >215 °C.

10.5 Incompatible materials

There is no additional information.

10.6 Hazardous decomposition products

Hazardous combustion products: see section 5.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Classification according to GHS (1272/2008/EC, CLP)

Acute toxicity

Shall not be classified as acutely toxic.

Acute toxicity

Exposure route	Endpoint	Value	Species	Method	Source
oral	LD50	>5.000 ^{mg} / _{kg}	rat		TOXNET

Skin corrosion/irritation

Shall not be classified as corrosive/irritant to skin.

Serious eye damage/eye irritation

Shall not be classified as seriously damaging to the eye or eye irritant.

Respiratory or skin sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.

Germ cell mutagenicity

Shall not be classified as germ cell mutagenic.

Carcinogenicity

Shall not be classified as carcinogenic.

Reproductive toxicity

Shall not be classified as a reproductive toxicant.

Specific target organ toxicity - single exposure

Shall not be classified as a specific target organ toxicant (single exposure).

Ireland (en) Page 8 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

Specific target organ toxicity - repeated exposure

Shall not be classified as a specific target organ toxicant (repeated exposure).

Aspiration hazard

Shall not be classified as presenting an aspiration hazard.

Symptoms related to the physical, chemical and toxicological characteristics

If swallowed

gastrointestinal complaints, nausea, vomiting, diarrhoea

• If in eyes

causes slight to moderate irritation

If inhaled

May produce an allergic reaction, cough, Dyspnoea, asthmatic complaints

• If on skin

May produce an allergic reaction, pruritis, localised redness

Other information

none

11.2 Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of $\geq 0.1\%$.

11.3 Information on other hazards

There is no additional information.

SECTION 12: Ecological information

12.1 Toxicity

Shall not be classified as hazardous to the aquatic environment.

12.2 Persistence and degradability

Theoretical Oxygen Demand (without nitrification): 1,551 $^{\rm mg}/_{\rm mg}$ Theoretical Oxygen Demand (with nitrification): 1,781 $^{\rm mg}/_{\rm mg}$ Theoretical Carbon Dioxide: 1,896 $^{\rm mg}/_{\rm mg}$

12.3 Bioaccumulative potential

Data are not available.

12.4 Mobility in soil

Data are not available.

12.5 Results of PBT and vPvB assessment

Data are not available.

12.6 Endocrine disrupting properties

Does not contain an endocrine disruptor (ED) at a concentration of $\geq 0.1\%$.

12.7 Other adverse effects

Data are not available.

Ireland (en) Page 9 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 13: Disposal considerations

13.1 Waste treatment methods



This material and its container must be disposed of as hazardous waste. Dispose of contents/container in accordance with local/regional/national/international regulations.

Sewage disposal-relevant information

Do not empty into drains.

Waste treatment of containers/packagings

Handle contaminated packages in the same way as the substance itself. Completely emptied packages can be recycled.

13.2 Relevant provisions relating to waste

The allocation of waste identity numbers/waste descriptions must be carried out according to the EEC, specific to the industry and process.

Properties of waste which render it hazardous

HP 13 sensitising

13.3 Remarks

Waste shall be separated into the categories that can be handled separately by the local or national waste management facilities. Please consider the relevant national or regional provisions. Non-contaminated packages may be recycled.

SECTION 14: Transport information

14.1	UN number or ID number	not subject to transport regulations

14.2 UN proper shipping name not assigned

14.3 Transport hazard class(es) none

14.4 Packing group not assigned

14.5 Environmental hazards non-environmentally hazardous acc. to the dan-

gerous goods regulations

14.6 Special precautions for user

There is no additional information.

14.7 Maritime transport in bulk according to IMO instruments

The cargo is not intended to be carried in bulk.

14.8 Information for each of the UN Model Regulations

International Maritime Dangerous Goods Code (IMDG) - Additional information Not subject to IMDG.

International Civil Aviation Organization (ICAO-IATA/DGR) - Additional information

Not subject to ICAO-IATA.

Ireland (en) Page 10 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

SECTION 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture Relevant provisions of the European Union (EU)

Restrictions according to REACH, Annex XVII

Dangerous substances with restrictions (REACH, Annex XVII)					
Name of substance	Name acc. to inventory	CAS No	Restriction	No	
Ampicillin sodium salt	substances in tattoo inks and perman- ent make-up		R75	75	

Legend

1. Shall not be placed on the market in mixtures for use for tattooing purposes, and mixtures containing any such substances shall not be used for tattooing purposes, after 4 January 2022 if the substance or substances in question is or are present in the following circumstances:

(a) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as carcinogen category 1A, 1B or 2, or germ cell mutagen category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight;
(b) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as reproductive toxicant

category 1A, 1B or 2, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by

(c) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin sensitiser category 1, 1A or 1B, the substance is present in the mixture in a concentration equal to or greater than 0,001 % by weight;

(d) in the case of a substance classified in Part 3 of Annex VI to Regulation (EC) No 1272/2008 as skin corrosive category 1, 1A, 1B or 1C or skin irritant category 2, or as serious eye damage category 1 or eye irritant category 2, the substance is present in the mixture in a concentration equal to or greater than:

substance is present in the mixture in a concentration equal to or greater than:
(i) 0,1 % by weight, if the substance is used solely as a pH regulator;
(ii) 0,01 % by weight, in all other cases;
(e) in the case of a substance listed in Annex II to Regulation (EC) No 1223/2009 (*1), the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight;
(f) in the case of a substance for which a condition of one or more of the following kinds is specified in column g
(Product type, Body parts) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration equal to or greater than 0,00005 % by weight: (i) "Rinse-off products";

(ii) "Not to be used in products applied on mucous membranes";
(iii) "Not to be used in products";
(g) in the case of a substance for which a condition is specified in column h (Maximum concentration in ready for use preparation) or column i (Other) of the table in Annex IV to Regulation (EC) No 1223/2009, the substance is present in the mixture in a concentration, or in some other way, that does not accord with the condition specified in that column;
(h) in the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concentration of the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concentration.

(n) In the case of a substance listed in Appendix 13 to this Annex, the substance is present in the mixture in a concentration equal to or greater than the concentration limit specified for that substance in that Appendix.

2. For the purposes of this entry use of a mixture "for tattooing purposes" means injection or introduction of the mixture into a person's skin, mucous membrane or eyeball, by any process or procedure (including procedures commonly referred to as permanent make-up, cosmetic tattooing, micro-blading and micro-pigmentation), with the aim of making a mark or design on his or her body.

3. If a substance not listed in Appendix 13 falls within more than one of points (a) to (g) of paragraph 1, the strictest concentration limit laid down in the points in question shall apply to that substance. If a substance listed in Appendix 13 also falls within one or more of points (a) to (g) of paragraph 1, the concentration limit laid down in point (h) of paragraph 1 shall apply to that substance. paragraph 1 shall apply to that substance.

4. By way of derogation, paragraph 1 shall not apply to the following substances until 4 January 2023:
(a) Pigment Blue 15:3 (CI 74160, EC No 205-685-1, CAS No 147-14-8);
(b) Pigment Green 7 (CI 74260, EC No 215-524-7, CAS No 1328-53-6).

5. If Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended after 4 January 2021 to classify or re-classify a substance such that the substance then becomes caught by point (a), (b), (c) or (d) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the date of ap-

that it then falls within a different one of those points from the one within which it fell previously, and the date of application of that new or revised classification is after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect on the date of application of that new or revised classification.

6. If Annex II or Annex IV to Regulation (EC) No 1223/2009 is amended after 4 January 2021 to list or change the listing of a substance such that the substance then becomes caught by point (e), (f) or (g) of paragraph 1 of this entry, or such that it then falls within a different one of those points from the one within which it fell previously, and the amendment takes effect after the date referred to in paragraph 1 or, as the case may be, paragraph 4 of this entry, that amendment shall, for the purposes of applying this entry to that substance, be treated as taking effect from the date falling 18 months after entry into force of the act by which that amendment was made.

7. Suppliers placing a mixture on the market for use for tattooing purposes shall ensure that, after 4 January 2022, the mixture is marked with the following information:

(a) the statement "Mixture for use in tattoos or permanent make-up";

(a) the statement "Mixture for use in tattoos or permanent make-up";

(b) a reference number to uniquely identify the batch;
(c) the list of ingredients in accordance with the nomenclature established in the glossary of common ingredient names pursuant to Article 33 of Regulation (EC) No 1223/2009, or in the absence of a common ingredient name, the IUPAC name. In the absence of a common ingredient name or IUPAC name, the CAS and EC number. Ingredients shall be listed in descending order by weight or volume of the ingredients at the time of formulation. "Ingredient" means any substance added during the process of formulation and present in the mixture for use for tattooing purposes. Imputition of the ingredients of the process purities shall not be regarded as ingredients. If the name of a substance, used as ingredient within the meaning of

Page 11 / 15 Ireland (en)

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU

Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

Legend

this entry, is already required to be stated on the label in accordance with Regulation (EC) No 1272/2008, that ingredi-

ent does not need to be stated on the label in accordance with Regulation; (d) the additional statement "pH regulator" for substances falling under point (d)(i) of paragraph 1; (e) the statement "Contains nickel. Can cause allergic reactions." if the mixture contains nickel below the concentration limit specified in Appendix 13; (f) the statement "Contains chromium (VI). Can cause allergic reactions." if the mixture contains chromium (VI) below

the concentration limit specified in Appendix 13; (g) safety instructions for use insofar as they are not already required to be stated on the label by Regulation (EC) No 1272/2008.

The information shall be clearly visible, easily legible and marked in a way that is indelible. The information shall be written in the official language(s) of the Member State(s) where the mixture is placed on the

market, unless the Member State(s) concerned provide(s) otherwise. Where necessary because of the size of the package, the information listed in the first subparagraph, except for point (a), shall be included instead in the instructions for use.

Before using a mixture for tattooing purposes, the person using the mixture shall provide the person undergoing the procedure with the information marked on the package or included in the instructions for use pursuant to this paragraph.
8. Mixtures that do not contain the statement "Mixture for use in tattoos or permanent make-up" shall not be used for

tattooing purposes.

9. This entry does not apply to substances that are gases at temperature of 20 °C and pressure of 101,3 kPa, or generate a vapour pressure of more than 300 kPa at temperature of 50 °C, with the exception of formaldehyde (CAS No 50-00-0, EC No 200-001-8).

10. This entry does not apply to the placing on the market of a mixture for use for tattooing purposes, or to the use of a mixture for tattooing purposes, when placed on the market exclusively as a medical device or an accessory to a medical device, within the meaning of Regulation (EU) 2017/745, or when used exclusively as a medical device or an accessory to a medical device, within the same meaning. Where the placing on the market or use may not be exclusively as a medical device or an accessory to a medical device, the requirements of Regulation (EU) 2017/745 and of this Regulation shall apply cumulatively.

List of substances subject to authorisation (REACH, Annex XIV)/SVHC - candidate list

Not listed.

Seveso Directive

2012/	2012/18/EU (Seveso III)							
No	Dangerous substance/hazard categories	Qualifying quantity (tonnes) for the application of lower and upper-tier requirements	Notes					
	not assigned							

Deco-Paint Directive

VOC content	0 %
-------------	-----

Industrial Emissions Directive (IED)

VOC content 0 %		0 %
-----------------	--	-----

Directive on the restriction of the use of certain hazardous substances in electrical and electronic equipment (RoHS)

not listed

Regulation concerning the establishment of a European Pollutant Release and Transfer Register (PRTR)

not listed

Water Framework Directive (WFD)

Page 12 / 15 Ireland (en)

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

List of pollutants (WFD)

Name of substance	Name acc. to inventory	CAS No	Listed in	Remarks
Ampicillin sodium salt	Metals and their compounds		a)	

Legend

Indicative list of the main pollutants

Regulation on the marketing and use of explosives precursors

not listed

Regulation on drug precursors

not listed

Regulation on substances that deplete the ozone layer (ODS)

not listed

Regulation concerning the export and import of hazardous chemicals (PIC)

Regulation on persistent organic pollutants (POP)

not listed

Other information

Directive 94/33/EC on the protection of young people at work. Observe employment restrictions under the Maternity Protection Directive (92/85/EEC) for expectant or nursing mothers.

National inventories

Country	Inventory	Status
CN	IECSC	substance is listed
EU	ECSI	substance is listed
JP	CSCL-ENCS	substance is listed
KR	KECI	substance is listed
NZ	NZIoC	substance is listed
TR	CICR	substance is listed
TW	TCSI	substance is listed
VN	NCI	substance is listed

Legend

CICR

CSCL-ENCS ECSI

Chemical Inventory and Control Regulation List of Existing and New Chemical Substances (CSCL-ENCS) EC Substance Inventory (EINECS, ELINCS, NLP) Inventory of Existing Chemical Substances Produced or Imported in China IECSC

Korea Existing Chemicals Inventory National Chemical Inventory New Zealand Inventory of Chemicals Taiwan Chemical Substance Inventory KECI NZIoC

15.2 Chemical safety assessment

No Chemical Safety Assessment has been carried out for this substance.

Ireland (en) Page 13 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: **HP62**

SECTION 16: Other information

Indication of changes (revised safety data sheet)

Section	Former entry (text/value)	Actual entry (text/value)	Safety- relev- ant
2.3		Endocrine disrupting properties: Does not contain an endocrine disruptor (ED) at a concentration of ≥ 0,1%.	yes
14.8	Transport of dangerous goods by road, rail and inland waterway (ADR/RID/ADN) - Additional information: Not subject to ADR, RID and ADN.		yes
15.1		National inventories: change in the listing (table)	yes

Abbreviations and acronyms

Abbreviations and acronyms		
Abbr.	Descriptions of used abbreviations	
ADR	Accord relatif au transport international des marchandises dangereuses par route (Agreement concerning the International Carriage of Dangerous Goods by Road)	
CAS	Chemical Abstracts Service (service that maintains the most comprehensive list of chemical substances)	
Ceiling-C	Ceiling value	
CLP	Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures	
DGR	Dangerous Goods Regulations (see IATA/DGR)	
EC No	The EC Inventory (EINECS, ELINCS and the NLP-list) is the source for the seven-digit EC number, an identifier of substances commercially available within the EU (European Union)	
ED	Endocrine disruptor	
EINECS	European Inventory of Existing Commercial Chemical Substances	
ELINCS	European List of Notified Chemical Substances	
GHS	"Globally Harmonized System of Classification and Labelling of Chemicals" developed by the United Nations	
IATA	International Air Transport Association	
IATA/DGR	Dangerous Goods Regulations (DGR) for the air transport (IATA)	
ICAO	International Civil Aviation Organization	
IMDG	International Maritime Dangerous Goods Code	
LD50	Lethal Dose 50 %: the LD50 corresponds to the dose of a tested substance causing 50 % lethality during a specified time interval	
NLP	No-Longer Polymer	
PBT	Persistent, Bioaccumulative and Toxic	
REACH	Registration, Evaluation, Authorisation and Restriction of Chemicals	
RID	Règlement concernant le transport International ferroviaire des marchandises Dangereuses (Regula- tions concerning the International carriage of Dangerous goods by Rail)	
S.I. No. 619 of 2001	Safety, Health and Welfare at Work (Chemical Agents) Regulations 2001	
STEL	Short-term exposure limit	

Ireland (en) Page 14 / 15

according to Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU



Ampicillin sodium salt CELLPURE® ≥ 91%

article number: HP62

Abbr.	Descriptions of used abbreviations
SVHC	Substance of Very High Concern
TWA	Time-weighted average
VOC	Volatile Organic Compounds
vPvB	Very Persistent and very Bioaccumulative

Key literature references and sources for data

Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures. Regulation (EC) No. 1907/2006 (REACH), amended by 2020/878/EU.

Agreement concerning the International Carriage of Dangerous Goods by Road (ADR). Regulations concerning the International Carriage of Dangerous Goods by Rail (RID). International Maritime Dangerous Goods Code (IMDG). Dangerous Goods Regulations (DGR) for the air transport (IATA).

List of relevant phrases (code and full text as stated in section 2 and 3)

Code	Text
H317	May cause an allergic skin reaction.
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Disclaimer

This information is based upon the present state of our knowledge. This SDS has been compiled and is solely intended for this product.

Ireland (en) Page 15 / 15